Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $34.2 million.

  • CytomX Therapeutics' Cash & Equivalents fell 1575.07% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.2 million, marking a year-over-year decrease of 1575.07%. This contributed to the annual value of $38.1 million for FY2024, which is 12160.62% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Cash & Equivalents of $34.2 million as of Q3 2025, which was down 1575.07% from $49.0 million recorded in Q2 2025.
  • CytomX Therapeutics' Cash & Equivalents' 5-year high stood at $329.7 million during Q1 2021, with a 5-year trough of $17.2 million in Q4 2023.
  • For the 5-year period, CytomX Therapeutics' Cash & Equivalents averaged around $108.2 million, with its median value being $56.4 million (2023).
  • As far as peak fluctuations go, CytomX Therapeutics' Cash & Equivalents surged by 13007.55% in 2021, and later tumbled by 9113.3% in 2023.
  • Over the past 5 years, CytomX Therapeutics' Cash & Equivalents (Quarter) stood at $205.5 million in 2021, then dropped by 5.78% to $193.6 million in 2022, then tumbled by 91.13% to $17.2 million in 2023, then skyrocketed by 121.61% to $38.1 million in 2024, then dropped by 10.16% to $34.2 million in 2025.
  • Its Cash & Equivalents stands at $34.2 million for Q3 2025, versus $49.0 million for Q2 2025 and $47.6 million for Q1 2025.